Patients with cancer often experience concomitant cardiovascular disease that results from the malignant process itself, or from anticancer treatment. Treatment-induced cardiotoxicity can be either transient or irreversible, and is associated with arrhythmia, ischaemia, and myocardial infarction. The authors discuss the mechanisms by which anticancer treatments damage the heart, and suggest potential strategies on how to protect patients with cancer from anticancer therapy-induced cardiotoxicity.
- Michael S. Ewer
- Steven M. Ewer
